SCHEMBL10243703

SCHEMBL10243703

O=C(c1ccccc1F)N1[C@@H]2CC[C@H]1C[C@@H](c1ccc(F)cc1)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
SLC18A3 Q16572 3/20 0.50
KDM4E B2RXH2 3/20 0.50
SIGMAR1 Q99720 2/20 0.50
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD11B1 P28845 1/20 0.48
DRD2 P14416 3/20 0.46
DRD4 P21917 3/20 0.46
HTR1A P08908 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HRH1 P35367 1/20 0.46
KCNK3 O14649 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
CCR5 P51681 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17350778 1.00 MEN1 (0.50) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL10244093 0.88 SLC18A3 (0.49) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL17350818 0.88 SLC18A3 (0.49) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL10243863 0.87 HSD11B1 (0.50) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL10243903 0.87 HSD11B1 (0.51) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL17350802 0.87 HSD11B1 (0.51) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL17350960 0.87 HSD11B1 (0.50) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL10243751 0.85 KMT2A (0.52) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL17350865 0.85 KMT2A (0.52) MEN1KMT2ASLC18A3KDM4ESIGMAR1
SCHEMBL17350988 0.84 HSD11B1 (0.54) MEN1KMT2ASLC18A3KDM4ESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2318403-B1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use BOEHRINGER INGELHEIM INT (DE) 2015-12-23 EP disclosed
US-20120115853-A1 Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115853-A1 Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use HSD11B1, HSD11B2, HSD17B1 MEN1 3884/4885KMT2A 2551/4885SLC18A3 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.